Press release
Encephalopathy Pipeline Outlook Report 2024 (Updated)
Endometrial Cancer Pipeline
Key Takeaways from the Endometrial Cancer Pipeline Report
• Over 50+ Endometrial Cancer companies are evaluating 50+ Endometrial Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Endometrial Cancer market would significantly increase market revenue.
• The leading Endometrial Cancer companies working in the market include Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Promising Endometrial Cancer Pipeline Therapies in the various stages of development include Ridaforolimus, Envafolimab, MK-2870, Doxorubicin, Paclitaxel, Lenvatinib, and others.
• March 2024: Memorial Sloan Kettering Cancer Center announced a study of Phase 2 clinical trials for Pembrolizumab and Olaparib. The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination and whether it causes few or mild side effects in participants.
• March 2024: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Lenvatinib and Carboplatin. The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).
Request a sample and discover the recent advances in Endometrial Cancer Treatment Drugs @ Endometrial Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Endometrial Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Endometrial Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Endometrial Cancer clinical trial landscape.
Endometrial Cancer Overview
Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly.
Find out more about Endometrial Cancer Treatment Drugs @ Drugs for Endometrial Cancer Treatment- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Endometrial Cancer Emerging Drugs Profile
• LENVIMA: Merck & Co
Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.
• Mirvetuximab soravtansine: ImmunoGen
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.
• XMT 1660: Mersana Therapeutics
XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.
• VLS-1488: Volastra Therapeutics, Inc.
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra's innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.
Endometrial Cancer Therapeutics Assessment
There are approx. 50+ key Endometrial Cancer companies which are developing the Endometrial Cancer therapies. The Endometrial Cancer companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. Phase III include Merck & Co.
DelveInsight's Endometrial Cancer pipeline report covers around 50+ products under different phases of clinical development like
• Late-stage products (phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
Endometrial Cancer Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies
Learn more about the emerging Endometrial Cancer Pipeline Therapies @ Endometrial Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Endometrial Cancer Pipeline Report
• Coverage- Global
• Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Endometrial Cancer Companies- Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Endometrial Cancer Pipeline Therapies- Ridaforolimus, Envafolimab, MK-2870, Doxorubicin, Paclitaxel, Lenvatinib, and others.
Dive deep into rich insights for new drugs for Endometrial Cancer Treatment, Visit @ Endometrial Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Endometrial Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometrial Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. LENVIMA: Merck & Co
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Mirvetuximab soravtansine: ImmunoGen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. VLS-1488: Volastra Therapeutics, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Endometrial Cancer Key Companies
21. Endometrial Cancer Key Products
22. Endometrial Cancer - Unmet Needs
23. Endometrial Cancer - Market Drivers and Barriers
24. Endometrial Cancer - Future Perspectives and Conclusion
25. Endometrial Cancer Analyst Views
26. Endometrial Cancer Key Companies
27. Appendix
For further information on the Endometrial Cancer Pipeline therapeutics, reach out to Endometrial Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Encephalopathy Pipeline Outlook Report 2024 (Updated) here
News-ID: 3457356 • Views: …
More Releases from DelveInsight Business Research LLP
Colorectal Cancer Pipeline Drugs in Development Signal Major Shifts in the Treat …
DelveInsight's, "Colorectal Cancer Pipeline Insight 2025" report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Colorectal…
Idiopathic Pulmonary Fibrosis Pipeline Clinical Trial Insights Reveal Breakthrou …
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insights 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Idiopathic Pulmonary Fibrosis pipeline products in this…
Small Cell Lung Cancer Pipeline Clinical Trials Highlight Promising Drugs in Dev …
DelveInsight's, "Small Cell Lung Cancer Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Myelofibrosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Mark …
DelveInsight's, "Myelofibrosis Pipeline Insights 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis Pipeline…
More Releases for Endometrial
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Endometrial Cancer Treatment Industry Market Size Be by 2025?
In recent years, the market size for endometrial cancer treatment has experienced consistent growth. It is projected to increase from $31.04 billion in 2024 to $32.09 billion in 2025, indicating a compound annual growth rate (CAGR) of…
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Endometrial Cancer Treatment Market Size and Projected Growth Rate?
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to…
Endometrial Biopsy Cannulae Market 2023
The report presents detailed information regarding the prominent players and potential competitors in the Endometrial Biopsy Cannulae market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue, growth…
Hysteroscopic Endometrial Resection Market - Transforming Hysteroscopy, Enhancin …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Hysteroscopic Endometrial Resection Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Hysteroscopic Endometrial Resection provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Endometrial Ablation Market snapshot 2024
Global Endometrial Ablation Market: Snapshot
With the rising prevalence of gynecology disorders, such as polycystic ovarian disease (PCOD), abnormal vaginal bleeding, the global adoption of endometrial ablation procedures has increased significantly, leading to an impressive rise in the worldwide endometrial ablation market. Apart from this, the upswing in the incidence rate of cervical and endometrial cancer in women is also driving the growth of this market substantially across the world.
Download The…
Global Endometrial Ablation Market: Radiofrequency Endometrial Ablation Devices …
With the presence of large players, such as Hologic Corp., Boston Scientific Corp., Cooper Surgical Inc., Ethicon Inc., and Medtronic Plc at the global level, the worldwide market for endometrial ablation demonstrates a highly competitive landscape, finds a new research report by Transparency Market Research (TMR).
The market players are focusing aggressively on developing their offerings technologically, which is likely to lead to price differentiation, resulting in intense rivalry between these…
